Valitor to Present Preclinical Data on Long-Acting Anti-VEGF Therapy at ARVO

The biotechnology company's novel biopolymer technology aims to enable twice-yearly dosing for wet AMD treatment.

Apr. 7, 2026 at 12:03pm

Got story updates? Submit your updates here. ›

A highly structured abstract painting in muted blues, greens, and grays, featuring sweeping geometric arcs, concentric circles, and precise botanical spirals, conceptually representing the complex molecular structure and biological mechanisms of Valitor's new long-acting anti-VEGF therapy for wet age-related macular degeneration.Valitor's novel VLTR-559 therapy aims to revolutionize wet AMD treatment by providing long-lasting efficacy with only twice-yearly dosing.Berkeley Today

Valitor, a biotechnology company developing a new generation of ophthalmic medicines, announced it will present new preclinical data on its long-acting anti-VEGF biologic VLTR-559 at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. VLTR-559 is designed to enable twice-yearly dosing for the treatment of wet age-related macular degeneration (AMD) and has shown promising safety and efficacy in preclinical studies.

Why it matters

Current anti-VEGF therapies for wet AMD require frequent intravitreal injections, which can be burdensome for patients. Valitor's novel biopolymer technology aims to significantly extend the durability of anti-VEGF treatment, potentially reducing the treatment burden and improving long-term outcomes for patients with wet AMD.

The details

In preclinical studies, VLTR-559 exhibited safety and efficacy consistent with approved short-acting anti-VEGF therapies, but remained in ocular tissues including the retina three to four times longer than first-generation anti-VEGFs. This demonstrates unprecedented durability at the target site without losing potency. Valitor is now advancing VLTR-559 through IND-enabling activities.

  • Valitor will present the data in an oral presentation at the ARVO Annual Meeting on Sunday, May 3, 2026.
  • The presentation is scheduled for 3:30 - 3:45 p.m. MT.

The players

Valitor

A biotechnology company engineering a new generation of ophthalmic medicines, including the long-acting anti-VEGF therapy VLTR-559.

Livia Brier, Ph.D.

Director of Development at Valitor and the presenter of the VLTR-559 data at the ARVO Annual Meeting.

Got photos? Submit your photos here. ›

What they’re saying

“Unlike other methods of drug modification that are designed to modify individual drug properties, Valitor's novel approach allows for independent control of multiple drug attributes, including pharmacokinetic/pharmacodynamic properties, improved target engagement/tissue localization, therapeutic durability, and improved safety.”

— Valitor

What’s next

Valitor is advancing VLTR-559 through IND-enabling activities to prepare the therapy for clinical trials.

The takeaway

Valitor's novel biopolymer technology has the potential to significantly improve the treatment experience for patients with wet AMD by reducing the burden of frequent intravitreal injections. If successful in clinical trials, VLTR-559 could offer a new standard of care for this debilitating eye disease.